GEP20053454B - Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof - Google Patents

Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof

Info

Publication number
GEP20053454B
GEP20053454B GE4911A GEAP2001004911A GEP20053454B GE P20053454 B GEP20053454 B GE P20053454B GE 4911 A GE4911 A GE 4911A GE AP2001004911 A GEAP2001004911 A GE AP2001004911A GE P20053454 B GEP20053454 B GE P20053454B
Authority
GE
Georgia
Prior art keywords
composition containing
same
aryl fused
fused azapolycyclic
azapolycyclic compounds
Prior art date
Application number
GE4911A
Other languages
English (en)
Inventor
Paige Roanne Palmer Brooks
Jotham Wadsworth Coe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of GEP20053454B publication Critical patent/GEP20053454B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/24Camphidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
GE4911A 2000-02-25 2001-02-08 Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof GEP20053454B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
GEP20053454B true GEP20053454B (en) 2005-02-25

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
GE4911A GEP20053454B (en) 2000-02-25 2001-02-08 Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof

Country Status (40)

Country Link
US (3) US6605610B1 (US07205300-20070417-C00042.png)
EP (2) EP1259489B1 (US07205300-20070417-C00042.png)
JP (1) JP2003524002A (US07205300-20070417-C00042.png)
KR (1) KR100537976B1 (US07205300-20070417-C00042.png)
CN (1) CN1263745C (US07205300-20070417-C00042.png)
AP (1) AP1860A (US07205300-20070417-C00042.png)
AT (2) ATE453643T1 (US07205300-20070417-C00042.png)
AU (2) AU784081B2 (US07205300-20070417-C00042.png)
BG (1) BG65891B1 (US07205300-20070417-C00042.png)
BR (1) BR0108610A (US07205300-20070417-C00042.png)
CA (1) CA2401229C (US07205300-20070417-C00042.png)
CR (1) CR6726A (US07205300-20070417-C00042.png)
CU (1) CU23148A3 (US07205300-20070417-C00042.png)
CY (1) CY1105301T1 (US07205300-20070417-C00042.png)
CZ (1) CZ303203B6 (US07205300-20070417-C00042.png)
DE (2) DE60140965D1 (US07205300-20070417-C00042.png)
DK (2) DK1259489T3 (US07205300-20070417-C00042.png)
DZ (1) DZ3328A1 (US07205300-20070417-C00042.png)
EA (1) EA005316B1 (US07205300-20070417-C00042.png)
EE (1) EE200200475A (US07205300-20070417-C00042.png)
ES (2) ES2263640T3 (US07205300-20070417-C00042.png)
GE (1) GEP20053454B (US07205300-20070417-C00042.png)
HK (1) HK1050894A1 (US07205300-20070417-C00042.png)
HR (1) HRP20020700A2 (US07205300-20070417-C00042.png)
HU (1) HU229482B1 (US07205300-20070417-C00042.png)
IL (2) IL150639A0 (US07205300-20070417-C00042.png)
IS (1) IS2293B (US07205300-20070417-C00042.png)
MA (1) MA26875A1 (US07205300-20070417-C00042.png)
MX (1) MXPA02008311A (US07205300-20070417-C00042.png)
NO (1) NO323608B1 (US07205300-20070417-C00042.png)
NZ (1) NZ519973A (US07205300-20070417-C00042.png)
OA (1) OA12181A (US07205300-20070417-C00042.png)
PL (1) PL365163A1 (US07205300-20070417-C00042.png)
PT (1) PT1259489E (US07205300-20070417-C00042.png)
RS (1) RS51123B (US07205300-20070417-C00042.png)
SI (1) SI1259489T1 (US07205300-20070417-C00042.png)
SK (1) SK12042002A3 (US07205300-20070417-C00042.png)
UA (1) UA74813C2 (US07205300-20070417-C00042.png)
WO (1) WO2001062736A1 (US07205300-20070417-C00042.png)
ZA (1) ZA200206768B (US07205300-20070417-C00042.png)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000038I1 (de) * 1997-12-31 2008-11-13 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
KR100551183B1 (ko) * 2001-04-20 2006-02-13 화이자 프로덕츠 인크. 1,3-치환 인덴 및 아릴-융합 아자폴리시클릭 화합물의제조 방법
BR0213696A (pt) * 2001-10-31 2004-10-26 Pfizer Prod Inc Agonistas do receptor de acetilcolina nicotìnicos no tratamento da sìndrome de pernas inquietas
RU2004116320A (ru) * 2001-11-30 2005-10-10 Пфайзер Продактс Инк. (Us) Арилконденсированные азаполициклические соединения
ES2282492T3 (es) * 2001-11-30 2007-10-16 Pfizer Products Inc. Composiciones farmaceuticas de liberacion controlada orales de 5,8,14-triazatetraciclo (10.3.1.0(2,11).0(4,9)-hexadeca-2(11)3,5,7,9-pentaeno.
JP5084103B2 (ja) 2002-07-18 2012-11-28 サイトス バイオテクノロジー アーゲー ハプテン担体抱合体およびその用法
EP1554041B1 (en) * 2002-10-22 2012-05-23 EMD Millipore Corporation Multi-sided immersion formation of composite structures and method
WO2004048318A1 (en) * 2002-11-25 2004-06-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
WO2004063164A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
WO2004108725A1 (en) * 2003-06-04 2004-12-16 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane
EP1648872A2 (en) * 2003-07-21 2006-04-26 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
CA2541752C (en) 2003-10-14 2012-01-03 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
JP2007516275A (ja) * 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
KR20070098942A (ko) * 2005-02-24 2007-10-05 화이자 프로덕츠 인코포레이티드 고순도의 치환된 퀴녹살린의 제조 방법
BRPI0710914A2 (pt) * 2006-04-24 2011-09-27 Pfizer Prod Inc forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar
KR20090086071A (ko) * 2006-11-09 2009-08-10 화이자 프로덕츠 인코포레이티드 니코틴 중간체의 다형체
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
NZ586651A (en) * 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
CA2707671C (en) 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
WO2009071687A1 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Amidomethyl-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
CA2709774C (en) * 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
EP2396327A1 (en) 2009-02-11 2011-12-21 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
EP2438054A1 (en) * 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
KR20180101268A (ko) 2017-03-03 2018-09-12 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
CN114929235A (zh) * 2020-01-03 2022-08-19 布鲁奥科制药有限公司 用于治疗cns病症的化合物和组合物
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
DE122008000038I1 (de) * 1997-12-31 2008-11-13 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
PT1076650E (pt) 1998-04-29 2004-05-31 Pfizer Prod Inc Compostos azapoliciclicos fundidos com arilo
JP4676062B2 (ja) * 1999-01-29 2011-04-27 アボット・ラボラトリーズ ニコチン性アセチルコリン受容体リガンドとしてのジアザ2環式誘導体
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
WO2002074050A2 (en) * 2001-03-19 2002-09-26 Sloan Kettering Institute For Cancer Research Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor
EP1648872A2 (en) * 2003-07-21 2006-04-26 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
DE60120366T2 (de) 2007-07-05
KR20030005209A (ko) 2003-01-17
MXPA02008311A (es) 2002-12-09
AU2005234671B2 (en) 2008-04-17
HK1050894A1 (en) 2003-07-11
AU2874801A (en) 2001-09-03
MA26875A1 (fr) 2004-12-20
US7144882B2 (en) 2006-12-05
EP1619192B1 (en) 2009-12-30
OA12181A (en) 2006-05-09
US7205300B2 (en) 2007-04-17
NO323608B1 (no) 2007-06-18
JP2003524002A (ja) 2003-08-12
BR0108610A (pt) 2002-11-19
BG65891B1 (bg) 2010-04-30
ATE453643T1 (de) 2010-01-15
ES2336800T3 (es) 2010-04-16
US6605610B1 (en) 2003-08-12
EE200200475A (et) 2003-12-15
PL365163A1 (en) 2004-12-27
YU59602A (sh) 2005-06-10
US20030130261A1 (en) 2003-07-10
DK1619192T3 (da) 2010-03-29
AU784081B2 (en) 2006-02-02
CA2401229A1 (en) 2001-08-30
IS6459A (is) 2002-07-05
CN1263745C (zh) 2006-07-12
HRP20020700A2 (en) 2004-12-31
ATE328872T1 (de) 2006-06-15
DE60120366D1 (de) 2006-07-20
IL150639A (en) 2011-10-31
AP1860A (en) 2008-07-02
CZ303203B6 (cs) 2012-05-23
CY1105301T1 (el) 2010-03-03
KR100537976B1 (ko) 2005-12-21
HUP0204580A2 (hu) 2003-04-28
EA005316B1 (ru) 2004-12-30
ES2263640T3 (es) 2006-12-16
SK12042002A3 (sk) 2004-02-03
SI1259489T1 (sl) 2006-10-31
EP1619192A3 (en) 2006-03-22
EP1259489A1 (en) 2002-11-27
NO20024042D0 (no) 2002-08-23
HU229482B1 (en) 2014-01-28
DK1259489T3 (da) 2006-10-09
CA2401229C (en) 2007-10-02
CU23148A3 (es) 2006-06-29
IS2293B (is) 2007-10-15
CZ20022778A3 (cs) 2003-09-17
CN1406227A (zh) 2003-03-26
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
EA200200716A1 (ru) 2003-02-27
IL150639A0 (en) 2003-02-12
ZA200206768B (en) 2003-09-23
DE60140965D1 (de) 2010-02-11
BG106908A (bg) 2003-04-30
US20030130260A1 (en) 2003-07-10
AU2005234671A1 (en) 2005-12-15
EP1259489B1 (en) 2006-06-07
HUP0204580A3 (en) 2005-04-28
RS51123B (sr) 2010-10-31
AP2002002604A0 (en) 2002-09-30
CR6726A (es) 2003-10-28
EP1619192A2 (en) 2006-01-25
PT1259489E (pt) 2006-08-31
WO2001062736A1 (en) 2001-08-30
DZ3328A1 (US07205300-20070417-C00042.png) 2001-08-30
UA74813C2 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
GEP20053454B (en) Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
GEP20053530B (en) Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof
GEP20053479B (en) Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
GEP20043241B (en) Compounds for Treatment of Ischemia and Pharmaceutical Compositions Containing the Same
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
GEP20032896B (en) 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
GEP20043324B (en) Purine Derivatives
MY119403A (en) Novel compounds with analgesic effect.
GEP20043315B (en) Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof
NZ501066A (en) Pharmaceutical formulations containing voriconazole and sulphobutylether beta-cyclodextrin
JO2354B1 (en) New derivatives of aromatic fluoroglycosides and drugs containing these compounds and their use
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
GEP20033118B (en) Meta-Azacyclic Amino Benzoic Acid Compounds and Derivatives Thereof Being Integrin Inhibitors, Pharmaceutical Composition and Use Thereof
GEP20043179B (en) Halogenated Amidino Amino Acid Derivatives Useful as Nitric Oxide Synthase Inhibitors
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
KR960703863A (ko) 암 치료용 신규 비스-나프탈이미드(New Bis-naphthalimides for the Treatment of Cancer)
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
GEP20063754B (en) Quinoline Derivatives and Use Thereof as Antitumor Agents
NZ523606A (en) Pharmaceutical compositions and methods for use
GEP20032924B (en) Novel Furan Diarylmethylidene Derivatives, Method for Their Preparation and Pharmaceutical Composition